300 related articles for article (PubMed ID: 18580309)
21. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
23. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP).
Travaglino A; Raffone A; Gencarelli A; Neola D; Oliviero DA; Alfano R; Campanino MR; Cariati F; Zullo F; Mollo A; Insabato L
Pathol Res Pract; 2021 Oct; 226():153592. PubMed ID: 34481212
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
25. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas.
Zhai YL; Kobayashi Y; Mori A; Orii A; Nikaido T; Konishi I; Fujii S
Int J Gynecol Pathol; 1999 Jan; 18(1):20-8. PubMed ID: 9891238
[TBL] [Abstract][Full Text] [Related]
26. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
27. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
28. Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis.
Momeni-Boroujeni A; Yousefi E; Balakrishnan R; Riviere S; Kertowidjojo E; Hensley ML; Ladanyi M; Ellenson LH; Chiang S
Mod Pathol; 2023 Apr; 36(4):100084. PubMed ID: 36788080
[TBL] [Abstract][Full Text] [Related]
29. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
[TBL] [Abstract][Full Text] [Related]
30. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
[TBL] [Abstract][Full Text] [Related]
31. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
32. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.
Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX
Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133
[TBL] [Abstract][Full Text] [Related]
33. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
34. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
35. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical Profile of Uterine Leiomyoma With Bizarre Nuclei; Comparison With Conventional Leiomyoma, Smooth Muscle Tumors of Uncertain Malignant Potential and Leiomyosarcoma.
Dastranj Tabrizi A; Ghojazadeh M; Thagizadeh Anvar H; Vahedi A; Naji S; Mostafidi E; Berenjian S
Adv Pharm Bull; 2015 Dec; 5(Suppl 1):683-7. PubMed ID: 26793616
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
[TBL] [Abstract][Full Text] [Related]
38. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
39. Immunoexpression of p16 in uterine leiomyomas with infarct-type necrosis: an analysis of 35 cases.
Ip PP; Lim D; Cheung ANY; Oliva E
Histopathology; 2017 Nov; 71(5):743-750. PubMed ID: 28609585
[TBL] [Abstract][Full Text] [Related]
40. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]